Veterinary Medicines

Eurican DAP-LR

Not authorised
  • Canine distemper virus, strain BA5, Live
  • Canine adenovirus 2, strain DK13, Live
  • Canine parvovirus, strain CAG2, Live
  • Leptospira interrogans, serovar Canicola, strain 16070, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated
  • Rabies virus, strain G52, Inactivated
Download as PDF

Product identification

Medicine name:
Eurican DAP-LR
Active substance:
  • Canine distemper virus, strain BA5, Live
  • Canine adenovirus 2, strain DK13, Live
  • Canine parvovirus, strain CAG2, Live
  • Leptospira interrogans, serovar Canicola, strain 16070, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated
  • Rabies virus, strain G52, Inactivated
Target species:
  • Dog
  • Dog
Route of administration:
  • Subcutaneous use
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain BA5, Live
    10000.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine adenovirus 2, strain DK13, Live
    316.23
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain CAG2, Live
    10000.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Leptospira interrogans, serovar Canicola, strain 16070, Inactivated
    80.00
    percentage protection
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated
    80.00
    percentage protection
    /
    1.00
    millilitre(s)
  • Rabies virus, strain G52, Inactivated
    1.00
    international unit(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AJ05
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 396a/87
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 19/04/2022
Download